STOCK TITAN

Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary

Ryan Saadi, CEO of Tevogen Bio (Nasdaq: TVGN), congratulates Marc Benioff, CEO of Salesforce, on receiving the Yale Legend in Leadership Award. The award, established 35 years ago, celebrates CEOs who exemplify leadership. Saadi, a Yale alumnus and a member of the Yale School of Public Health Leadership Council, emphasizes the alignment of corporate success with social responsibility. He attended the bi-annual CEO Summit alongside other notable business leaders from companies like Palo Alto Networks, Xerox, Verizon, Bank of America, Disney, General Motors, Coca-Cola, and many more, reflecting a shared commitment to integrating business and social prosperity.

Positive
  • Recognition of leadership in integrating corporate success with social responsibility can enhance company reputation.
  • Exposure at the CEO Summit alongside influential business leaders highlights Tevogen Bio within a prominent network.
Negative
  • None.

WARREN, N.J., July 08, 2024 (GLOBE NEWSWIRE) -- Ryan Saadi, MD, MPH, founding CEO of Tevogen Bio (“Tevogen”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, congratulates Salesforce CEO Marc Benioff on receiving the Yale Legend in Leadership Award for highlighting that business success must coexist with social prosperity at the bi-annual CEO Summit. The Yale Legend in Leadership Award was created 35 years ago to honor current and former CEOs who serve as living legends to inspire chief executives across industries, sectors, and nations.

“I share Marc’s belief that business success must coexist with social prosperity,” said Dr. Ryan Saadi. “As a Yale graduate and a member of the Yale School of Public Health Leadership Council, it was a distinct pleasure to join Yale School of Management Senior Associate Dean, Jeffrey Sonnenfeld and business pioneers including Nikesh Arora, CEO, Palo Alto Networks; Steven Bandrowczak, CEO, Xerox; Ivan Seidenberg, Former Chair & CEO, Verizon; Brian Moynihan, Chair & CEO, Bank of America; Ken Moelis, Founder, Chair & CEO, Moelis & Company; Bob Iger, CEO, The Walt Disney Company; Jeffrey Bewkes, Former Chair & CEO, Time Warner; Mary Barra, Chair & CEO, General Motors; James Quincey, Chair & CEO, The Coca-Cola Company; Glenn Fogel, President & CEO, Booking Holdings; Michel Doukeris, CEO, Anheuser-Busch InBev; Jacek Olczak, CEO, Philip Morris International; Reuben Mark, Former CEO, Colgate-Palmolive Company; Michael Dell, Chair & CEO, Dell Technologies; Brian Tyler, CEO, McKesson Corporation; Christian Ulbrich, Global CEO, JLL; John W. Jackson, Former CEO, Celgene; James Taiclet, Chair, President & CEO, Lockheed Martin; Kathy Warden, Chair, President & CEO, Northrop Grumman; Lynn Good, Chair, President & CEO, Duke Energy; David Cote, Former Chair & CEO, Honeywell International; Arvind Krishna, Chair & CEO, IBM”.

About Tevogen Bio

Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.

Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.

Contacts

Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com


FAQ

What award did Marc Benioff receive in July 2024?

Marc Benioff received the Yale Legend in Leadership Award.

What is the significance of the Yale Legend in Leadership Award?

The Yale Legend in Leadership Award honors current and former CEOs who exemplify leadership and inspire executives globally.

Which company's stock symbol is TVGNW?

TVGNW is the stock symbol for Tevogen Bio.

Who congratulated Marc Benioff on his award in July 2024?

Ryan Saadi, CEO of Tevogen Bio, congratulated Marc Benioff.

Why did Ryan Saadi commend the Yale School of Management?

Ryan Saadi commended the Yale School of Management for recognizing the integration of corporate success with social responsibility.

Which notable business leaders attended the bi-annual CEO Summit with Ryan Saadi?

Leaders from companies like Palo Alto Networks, Xerox, Verizon, Bank of America, Disney, General Motors, Coca-Cola, and others attended.

Tevogen Bio Holdings Inc. Warrant

NASDAQ:TVGNW

TVGNW Rankings

TVGNW Latest News

TVGNW Stock Data

168.83M
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
WARREN